A study from Weill Cornell Medicine reports that activated T cells secrete extracellular vesicles (EVs) containing DNA that can enter other immune and tumor cells to enhance antigen processing and presentation. In preclinical mouse experiments across immunologically cold tumor models, the EV-associated DNA increased antigen presentation and dendritic cell activation. The investigators reported that activated T cell-derived EVs (AT-EVs) synergized with immune checkpoint inhibitors to trigger stronger antitumor immunity and hold tumor growth in check. The work frames the EV-DNA mechanism as a possible acellular immunotherapy strategy for cancers that otherwise show weak immune engagement. The research was published in the journal Cancer Cell and highlighted a “positive feedback loop” concept where AT-EVs improve antigen presentation, potentially amplifying T cell responses. David Lyden, MD, PhD, co-senior author, described the findings as a route to treat “immunologically silent tumors” and expand therapeutic delivery concepts for genetic payloads.